# Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy

> **NCT02439216** · PHASE1,PHASE2 · COMPLETED · sponsor: **Catabasis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Muscular Dystrophy, Duchenne

## Interventions

- **DRUG:** Edasalonexent
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02439216
- **Lead sponsor:** Catabasis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-01-12
- **Final completion:** 2019-08
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02439216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02439216, "Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02439216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*